(Last updated : 2020-06-24 11:19:30)
  瀧川 奈義夫
   Department     ,
   Position  
■ Present specialized field
Respiratory medicine, Molecular biology, General internal medicine (Key Word:drug resistance, molecular target, chemotherapy, immunotherapy) 
■ BooK
1. 2015/08   Cancer Stem Cells and Chemoresistance, Stem Cells in Modeling Human Genetic Diseases 
2. 2011/09   “Hairy morphology” of hairy cell leukemia-Japanese variant may disappear under specific conditions, BloodMed 
■ Journal
1. 2020/04/09 Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab following Tubulointerstitial Nephritis due to Pembrolizumab.  Link
2. 2020/01 Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.  Link
3. 2019/12/02 De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor.  Link
4. 2019/08 A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.  Link
5. 2019/07 Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.  Link
Display all(171)
■ Presentation
1. 2019/04/02 Development of an integrated CRISPR interference system targeting Np63 to treat lung and esophageal squamous cell carcinoma.  
2. 2018/09/28 Targeted silencing of SOX2 by an ATF showed antitumor effect in lung and esophageal squamous cell carcinoma  
3. 2018/07/20 Patients with osteosarcoma and soft tissue sarcoma tend to become cancer refugees in
Japanese regional cities  
4. 2018/04/16 Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma  
5. 2017/09/09 Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations (OLCSG1303)  
Display all(67)